The difference in OS based on TP53 mutation status was particularly striking in breast, prostate, and uterine cancers and less striking in NSCLC, colon, ovarian, and pancreatic cancers (Supplementary Fig. S4F–S4L). The gene discussed is TP53; the disease is non-small cell lung carcinoma.